Zacks Industry Outlook Highlights: Affymetrix, The Cooper Co., Align Technology and AmSurg

     Zacks Industry Outlook Highlights: Affymetrix, The Cooper Co., Align
                            Technology and AmSurg

PR Newswire

CHICAGO, Sept. 11, 2013

CHICAGO, Sept. 11, 2013 /PRNewswire/ --Today, Zacks Equity Research discusses
the U.S. MedTech (Medical Technology), including Affymetrix Inc.
(Nasdaq:AFFX-Free Report) The Cooper Companies Inc. (NYSE:COO-Free Report),
Align Technology (Nasdaq:ALGN-Free Report) and AmSurg Corp. (Nasdaq:AMSG-Free
Report).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Industry: MedTech (Medical Technology)

Link:
http://www.zacks.com/commentary/28930/MedTech-Industry-Stock-Update---Sept-2013

In spite of several core market challenges, the big two medical device players
-- Medtronic and Boston Scientific -- are striving to gain share in the ICD
market through several new product launches. They are also exploring new
avenues of growth beyond the mature pacemaker and ICD markets. With gradual
stability in the ICD market, they should be able to revive their top line.
Also, better pipeline visibility and appropriate utilization of cash should
increase confidence in the medical device sector.

Microarray product maker Affymetrix Inc. (Nasdaq:AFFX-Free Report) was
languishing with its flagship GeneChip Expression products until management
found a strategy to expand into high-growth markets for translational
medicine, molecular diagnostics and applied markets. Consequently the shares
of Affymetrix hit a 52-week high accompanied by a bullish Zacks Rank #1
(Strong Buy).

Zacks Rank #2 (Buy) stocks in the MedTech sector includeThe Cooper Companies
Inc. (NYSE:COO-Free Report) and Boston Scientific among others. Cooper
represents a value proposition based on factors such as margin expansion,
acquisitions, product line expansion and geographical reach as well as share
buybacks. On the other hand, we are positive about multiple initiatives taken
by Boston Scientific to expand electrophysiology (EP) division.

Zacks Ranked #3 St. Jude is also doing well with its growing Atrial
Fibrillation products portfolio that witnessed a major boost with the
acquisition of Endosense and regulatory approval for its Mediguide catheters.

Beyond the MedTech majors, we are also optimistic about the Zacks Ranked #3
orthopedic device players, Zimmer Holdings and Stryker Corporation. The
percentage of population over 65 in the U.S., Europe, Japan and other regions
is expected to nearly double by the year 2030. In the U.S., the oldest baby
boomers are now approaching retirement age. We believe the orthopedic giants
stand to benefit from this aging demography.

Among scientific instrument makers, Thermo Fisher Scientific has been
successfully expanding operating margins over the past few quarters on the
back of operational efficiency. Thermo Fisher's market leading portfolio of
analytical technologies and specialty diagnostic will be complemented by the
upcoming buyout of Life Technologies. The latter has an expansive line of
consumables for genomic, molecular and cell biology.

Among mid-cap MedTech stocks, Align Technology (Nasdaq:ALGN-Free Report) and
AmSurg Corp. (Nasdaq:AMSG-Free Report) carrying a Zacks Rank #2 (Buy) look
attractive.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Click here for your free subscription to Profit from
the Pros.

Get the full Report on AFFX - FREE

Get the full Report on COO – FREE

Get the full Report on ALGN - FREE

Get the full Report on AMSG - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such
affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit
http://www.zacks.com/performance for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com
 
Press spacebar to pause and continue. Press esc to stop.